title: Tumor angiogenesis in melanoma.
abstract: A large number of clinical studies are being conducted to assess the effects of angiogenesis inhibitors in the treatment of patients who have metastatic melanoma. It has become increasingly clear that a therapeutic approach that combines angiogenesis inhibitors with cytotoxic agents or other treatment modalities is more likely to result in a clinical benefit for patients rather than antiangiogenesis treatments alone. However, a targeted treatment approach with antiangiogenic agents needs to be based on an in-depth understanding of the complex mechanisms involved in melanoma tumor angiogenesis.
authors.affiliation: Cutaneous Biology Research Center, Massachusetts General Hospital, Building 149, 13th Street, Charlestown, MA 02129, USA. alexander_marneros@yahoo.com
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Marneros
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018925:Chemokines / Q000502:physiology; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016503:Drug Delivery Systems; D042783:Endothelial Cells / Q000473:pathology; D005347:Fibroblasts / Q000473:pathology; D006801:Humans; D008545:Melanoma / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy; D045164:Mesenchymal Stem Cell Transplantation; D051379:Mice; D022423:Myeloid Cells / Q000473:pathology; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D013234:Stem Cells / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D018925:Chemokines; D009363:Neoplasm Proteins; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A